Latest news with #ETON
Time of India
2 days ago
- Health
- Time of India
Prolonged use of ethambutol leads to vision loss in TB patients, says study by doctors of LV Prasad Eye Institute
Hyderabad: A recent study conducted by the doctors at the LV Prasad Eye Institute (LVPEI) raised concerns about severe vision loss caused by ethambutol, a drug commonly used to treat tuberculosis (TB). Published in the Indian Journal of Ophthalmology, the study reveals that prolonged use of ethambutol, which is used as part of India's TB treatment programme due to its relatively low toxicity, combined with higher dosages, is linked to a sharp rise in cases of ethambutol-induced toxic optic neuropathy (ETON). It is a condition that damages the optic nerve and impacts vision. The study also pointed out that the Central govt's National TB Elimination Programme (NTEP), which is implemented across the country, including in Telangana, uses ethambutol extensively. In 2016, the NTEP extended the use of ethambutol from two to six months and also increased the dosage frequency to once daily from thrice a week. Since then, the ETON cases increased sixfold within three years. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad During the research, the LVPEI doctors examined 107 patients suffering from ETON, with around 58% of them being middle-aged (36 to 55 years), who took the drug for seven consecutive months. Doctors found that almost all of the patients experienced severe vision loss in both eyes, with the elderly (above 60 years) being the worst affected, despite the low toxicity levels of the drug. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Your IQ Is 140 If You Can Answer 10 of These Questions Correctly. IQ International Undo However, after they discontinued ethambutol, an 11-month follow-up found that the vision clarity of the patients started improving, except for the elderly. 'ETON has become more common and can lead to severe vision loss, especially in the elderly, individuals with low body weight, and those with kidney problems (renal dysfunction). Symptomps include change in vision, contrast or colour vision. There are smartphone-based apps which the patients can use to check vision and colour vision at home. Dosage should be recommended as per body weight, age and kidney function. Careful monitoring and early discontinuation of the drug are essential to prevent vision loss,' said Dr Virender Sachdeva, one of the authors. In March this year, the World Health Organisation (WHO) pointed out that while India showed significant progress in reducing TB cases and improved treatment coverage, it is unlikely to meet the 2025 target set by the WHO's 'End TB Strategy'. WHO's Global Tuberculosis Report 2024 stated that India had 26% of global TB cases and 26% of global deaths in 2023, the highest in the world. According to officials in the Telangana health, family, and welfare dept, currently around 81 lakh people of the over 3.5 crore population (20%) in Telangana are TB-prone, with 10 lakh alone in Hyderabad. Official numbers tabled in Parliament showed that Telangana recorded 1.37 lakh TB cases and 2,663 deaths from July 2023 to Dec 2024. Noting that the findings of the study will be reviewed, senior officials of the TB programme, health dept, said, 'After completing the 100-day action plan, we again launched a continuous plan in June this year to boost TB screening, awareness, and care in Hyderabad, rural areas, and urban slums. Special emphasis is being given to people above 60 years, those who drink and smoke, previous TB patients, family members of the present TB patients, and people with comorbidities. '
Yahoo
3 days ago
- Business
- Yahoo
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ('Eton' or the 'Company') (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In: (800) 715-9871 or (646) 307-1963; Conference ID: 5899895 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@ live webcast can also be accessed on the Investors section of Eton's website at An archived webcast will be available on Eton's website approximately two hours after the completion of the event and for 30 days thereafter. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at Investor Relations: Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: lwilson@ Source: Eton Pharmaceuticals, Inc.
Yahoo
02-06-2025
- Business
- Yahoo
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness. There are several stocks that passed through the screen and (ETON) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. ETON is quite a good fit in this regard, gaining 29.5% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 8.9% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, ETON is currently trading at 85.9% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout. Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance. So, the price trend in ETON may not reverse anytime soon. In addition to ETON, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria. This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market. However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies. Click here to sign up for a free trial to the Research Wizard today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eton Pharmaceuticals, Inc. (ETON) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received FDA approval for KHINDIVI, the first and only hydrocortisone oral solution available in the United States, marking a major milestone for pediatric care. Designed for children aged five and older with adrenocortical insufficiency, a rare disorder where the adrenal glands do not produce enough cortisol, KHINDIVI offers a 1mg/ml ready-to-use liquid formulation. This eliminates the need for splitting or crushing tablets and allows for precise, incremental dosing tailored to each child's needs. The solution does not require refrigeration, mixing, or shaking, making it especially suitable for patients who have trouble swallowing pills or need administration via a gastric tube. A clinical researcher in a lab examining a new biopharmaceutical product. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) expects to launch KHINDIVI commercially the week of June 2, with combined peak sales from KHINDIVI and its companion product, ALKINDI SPRINKLE, projected to exceed $50 million annually. The medication will be distributed exclusively through Anovo, a specialty pharmacy, and supported by the Eton Cares Program, which provides prescription fulfillment, insurance support, educational resources, and co-pay assistance. This FDA approval is seen as a significant advancement for families and clinicians managing pediatric adrenal insufficiency, offering a new, accurate, and accessible treatment option. While we acknowledge the potential of ETON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ETON and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
29-05-2025
- Business
- Business Insider
Eton Pharmaceuticals announces FDA approval for KHINDIVI
Eton Pharmaceuticals (ETON) 'announced the U.S. Food and Drug Administration approval of a New Drug Application for KHINDIVI Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. KHINDIVI is the only FDA-approved oral solution formulation of hydrocortisone. It comes in a 1mg/ml strength designed to eliminate the need to split or crush tablets, and to offer simple and accurate dosing specifically tailored to each patient's needs. It does not require refrigeration, mixing, or shaking – it is a ready-to-use oral liquid solution. KHINDIVI is designed to offer administration simplicity and dosing accuracy, and to provide a therapy option for patients who have difficulty swallowing tablets or with special administration needs, such as patients with a gastric tube. Adrenocortical insufficiency is a rare, but serious condition in which the adrenal glands do not produce sufficient cortisol. Eton estimates that there are more than 5,000 adrenal insufficiency patients in the U.S. between the ages of 5 and 17, and expects peak sales of KHINDIVI, combined with ALKINDI SPRINKLE, will exceed $50 million per year. KHINDIVI will be available in the coming days in the United States exclusively through Anovo, a specialty pharmacy dedicated to serving patients with rare and chronic conditions. Anovo will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program provides prescription fulfillment, insurance benefits investigation, educational support, financial assistance for qualified patients, and other services designed to help patients access treatment. Eton Cares will offer co-pay assistance to allow for $0 co-pays for qualifying patients.' Confident Investing Starts Here:
